Icatibant Aspire Pharma

Icatibant, the active ingredient in Icatibant Aspire Pharma, is a bradykinin B2 receptor antagonist presented as an injection solution for subcutaneous use. It is indicated for the treatment of hereditary angioedema attacks in patients with C1‑inhibitor deficiency, helping to reduce swelling and improve airway safety.

GNH USA supplies Icatibant Aspire Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing and regulatory support for global healthcare providers.

Icatibant targets the bradykinin‑mediated pathway in hereditary angioedema.

Hereditary angioedema (C1‑inhibitor deficiency): reduces the severity and duration of acute swelling attacks. Hereditary angioedema type I and II: provides rapid symptom relief during attacks. Hereditary angioedema attacks: improves airway patency and patient comfort.

Icatibant may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling at injection site: localized erythema. - Nausea: transient feeling of queasiness. - Headache: mild to moderate intensity.

Serious or Rare Side Effects: - Hypersensitivity reactions: rash, urticaria, or angioedema. - Anaphylaxis: severe, potentially life‑threatening allergic response. - Severe hypotension: sudden drop in blood pressure. - Airway edema: swelling that may compromise breathing.

When using Icatibant, certain precautions should be observed to ensure safe administration. - Pregnancy: safety not established; use only if benefit outweighs risk. - Breastfeeding: unknown safety; consider potential risks. - Renal impairment: no dosage adjustment required, but monitor renal function. - Concomitant ACE inhibitors: may increase bradykinin levels; monitor for edema. - Hypersensitivity: discontinue if severe allergic reaction occurs. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medicines that affect bradykinin pathways or vascular tone.

Major Interactions (Avoid): - ACE inhibitors: additive bradykinin effect may worsen angioedema. - Neprilysin inhibitors: increased bradykinin levels; avoid combined use. - C1‑inhibitor concentrates used simultaneously: may alter clinical response.

Moderate Interactions (Monitor Closely): - Estrogen‑containing contraceptives: may increase frequency of attacks; monitor. - Diuretics: may affect fluid balance; observe patient status. - Other B2 receptor antagonists: additive effects; adjust dosing as needed.